Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Aug 5, 2024 | Non-Hodgkin Lymphoma
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Aug 5, 2024 | Non-Hodgkin Lymphoma
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation Feb 29, 2024 | Uncategorized
Quality of Life in the Phase 2/3 Trial of N-803 Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Feb 9, 2024 | Uncategorized
